Anticoagulation Therapy

Phase 3Small molecule

Anticoagulation Therapy is one of 53 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismRecruiting

Atrial FibrillationActive, not recruiting

Cerebral Venous Sinus ThrombosisRecruiting

Venous ThromboembolismPhase 3

Recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Cerebral Venous Sinus ThrombosisPreclinical

Recruiting

Competition

Competitive Landscape

136 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Anticoagulation Therapy

OOhio State University

Phase 3

2 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Coumadin

3 5

Imbruvica

PPharmacyclics LLC.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Brukinsa

BBeOne Medicines

Preclinical

1 8

Statin

Bristol-Myers Squibb

Preclinical

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

Direct Anticoagulant

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

ApprovedRecruiting

Venous Thromboembolism

NCT06603870

Q1 2030

PreclinicalRecruiting

Cerebral Venous Sinus Thrombosis

NCT07548346

Clinical

Trials by Indication[1]

Atrial Fibrillation2 trials

Stand-alone Totally Thoracoscopic Left Atrial Appendage Occlusion Using AtriClip® Device in Non-valvular Atrial Fibrillation.

Unknown status·CCentral Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland··NCT03838341·100 enrolled

Atrial Fibrillation Burden and Long-term Risk of Thromboembolic Complications- the FinCV-4 Study

Active, not recruiting·UUniversity of Turku··NCT04001205·1,300 enrolled

Atrial Appendage1 trial

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Completed·AAtriCure, Inc.·Phase 4·NCT02701062·562 enrolled

Statin1 trial

Statin Use in Patients With Acute VTE

Terminated·OOhio State University·Phase 1·NCT02331095·21 enrolled

Antithrombotic1 trial

Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR

Unknown status·CChina National Center for Cardiovascular Diseases·Phase 4·NCT05375474·650 enrolled

Chronic Liver Disease1 trial

Safety of Anticoagulation Therapy in Cirrhotic Patients With Portal Vein Thrombosis and Severe Thrombocytopenia as Long as Platelet Counts no Less Than 30×10^9/L

Completed·QQilu Hospital of Shandong University··NCT07885969·304 enrolled

2 more indications

Cerebral Venous Sinus Thrombosis1 trial

REVIVE-CVST: A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint (PROBE) Trial of Endovascular Thrombectomy Plus Standard Medical Care Versus Standard Medical Care Alone in Adults With Acute or Subacute Cerebral Venous Sinus Thrombosis at High Risk of Poor Outcome in the Middle East and North Africa Region

Recruiting·MMiddle East North Africa Stroke and Interventional Neurotherapies Organization·Preclinical·NCT07548346·440 enrolled

Venous Thromboembolism1 trial

Secondary Prevention of Venous Thromboembolism in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (STREAM-Line Study)

Recruiting·OOttawa Hospital Research Institute·Approved·NCT06603870·330 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Anticoagulation Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anticoagulation Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anticoagulation Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ohio State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOhio State University

Anticoagulation Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q1 2030

Trials by Indication[1]

Atrial Fibrillation2 trials

Atrial Appendage1 trial

Statin1 trial

Antithrombotic1 trial

Chronic Liver Disease1 trial

Cerebral Venous Sinus Thrombosis1 trial

Venous Thromboembolism1 trial

References

Drug Info

Quick Facts

Related News